Table 2 Overview of miRNA utilization for cancer screening and diagnosis in clinical trials
From: The potential of microRNAs in cancer diagnostic and therapeutic strategies: a narrative review
miR(s) | Role | Cancer type | Methods | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
miR-155 | Diagnostic biomarker | Bladder cancer | qRT-PCR | NCT03591367 |
miR panel | Screening tools | Multicentric breast cancer | Not provided | NCT04516330 |
5 miR index (endometrial cancer), and miR-200b (ovarian cancer) | Diagnostic biomarkers | Ovarian and endometrial cancer | qRT-PCR and high-throughput sequencing (RNA-seq) | NCT03776630 |
let-7a and miR-124 | Diagnostic biomarkers | Non-Hodgkin’s lymphoma and acute leukemia | Real-time PCR | NCT05477667 |
miR panel | Screening tools | Lung cancer | Custom-made microfluidic card | NCT02247453 |
Signature of the miRs | Diagnostic biomarkers | Thyroid cancer | NGS | NCT04285476 |
miR-421, miR-27a-3p | Screening tools | Colorectal cancer | qRT-PCR | NCT05346757 |
miR-194 | Diagnostic biomarker | Prostate cancer | Not provided | NCT04835454 |
miR panel | Screening tools | 42 tumor types | Microarray | miRview® mets (Available) |
miR-29, miR-155, miR-138, and miR-204, miR-139, miR-31, miR-375, miR-146, miR-551, miR-221, and miR-22 | Screening tools | Thyroid and pancreatic cancer | NGS | ThyraMIR®v2 (Available) |